The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis

<div>Overall survival for 1016 patients with newly diagnosed symptomatic multiple myeloma according to the ISS stages I, II, and III, who were treated with novel agents as the first-line strategy.</div>

BioMed Research International

fig2

Figure 2

Figure 2: The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis 

Figure 2 | The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis 